Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant neoplasm arising from the choroid plexus. It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)
Biomarker and diagnostic research for choroid plexus carcinoma has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
5 clinical trials registered, 3 recruiting. Interventions under study include biologic therapy, drug therapy, and other interventions. Pipeline includes 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04994977](https://clinicaltrials.gov/study/NCT04994977) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:00 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
PHASE1 |
Weill Medical College of Cornell University |
UNKNOWN |
[NCT06357377](https://clinicaltrials.gov/study/NCT06357377) | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | PHASE1 | Neonc Technologies, Inc. | RECRUITING |
[NCT03050268](https://clinicaltrials.gov/study/NCT03050268) | Familial Investigations of Childhood Cancer Predisposition | — | St. Jude Children's Research Hospital | RECRUITING |
[NCT04185038](https://clinicaltrials.gov/study/NCT04185038) | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | PHASE1 | Seattle Children's Hospital | RECRUITING |
[NCT03500991](https://clinicaltrials.gov/study/NCT03500991) | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | PHASE1 | Seattle Children's Hospital | ACTIVE_NOT_RECRUITING |
33 publications have been identified in PubMed for choroid plexus carcinoma. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (27%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 10 | 30% |
Research summaries | 9 | 27% |
Laboratory research | 6 | 18% |
Testing and diagnosis research | 2 | 6% |
Clinical study results | 2 | 6% |
Disease patterns and progression | 2 | 6% |
Other research | 1 | 3% |
New treatment approaches | 1 | 3% |
De Jesus O (2026). [PMID: 41744878](https://pubmed.ncbi.nlm.nih.gov/41744878/). *Curr Oncol*. [Review / Meta-Analysis]
Charolia MS (2026). [PMID: 41736349](https://pubmed.ncbi.nlm.nih.gov/41736349/). *J Pak Med Assoc*. [Review / Meta-Analysis]
Gatz SA (2026). [PMID: 41591981](https://pubmed.ncbi.nlm.nih.gov/41591981/). *Clin Cancer Res*. [Clinical Trial Publication]
Thompson A (2026). [PMID: 41942479](https://pubmed.ncbi.nlm.nih.gov/41942479/). *Oncogenesis*. [Review / Meta-Analysis]
Osorio DS (2025). [PMID: 41198335](https://pubmed.ncbi.nlm.nih.gov/41198335/). *Adv Cancer Res*. [Review / Meta-Analysis]
Erşen Danyeli A (2025). [PMID: 39988363](https://pubmed.ncbi.nlm.nih.gov/39988363/). *Neuropathology*. [Diagnostic / Biomarker]
Youssef M (2025). [PMID: 40709017](https://pubmed.ncbi.nlm.nih.gov/40709017/). *Neurooncol Adv*. [Case Report / Case Series]
Jassim A (2025). [PMID: 40578362](https://pubmed.ncbi.nlm.nih.gov/40578362/). *Cancer Cell*. [Gene Therapy / Novel Therapeutics]
Tan CL (2025). [PMID: 41625814](https://pubmed.ncbi.nlm.nih.gov/41625814/). *Cureus*. [Case Report / Case Series]
Smith HL (2025). [PMID: 41374972](https://pubmed.ncbi.nlm.nih.gov/41374972/). *Cancers (Basel)*. [Other]